August 2019 |
|
Grassley, Wyden Release Committee Summary Reports on Long-Term Solutions to Temporary Tax Policy
|
|
Grassley Pressures Drug Manufacturer over Data Manipulation
|
|
Grassley Urges HHS, FDA to Implement Unannounced Inspections of Foreign Drug Manufacturing Facilities
|
|
Grassley Presses Comptroller General on Foreign Threats to Taxpayer-funded Research
|
|
Grassley Receives Response from IRS on Noncompliance Inquiry
|
July 2019 |
|
Grassley On Treasury, Tax Court Nominations Open Executive Session
|
|
Grassley: Goldilocks Moment to Reduce Rx Prices
|
|
Congress Passes Grassley Legislation to Help Children with Special Health Care Needs
|
|
Grassley On the Benefits of USMCA: Vilsack Testifies
|
|
ICYMI: Libertarian Cato Institute Supports Finance Committee’s Medicare Part D Reforms
|
|
Grassley Statement on Newly-Released GAO Report on Medicaid Supplemental Payments
|
|
Grassley on Spread Pricing
|
|
The Benefits of USMCA
|
|
Grassley’s Rx Bill Passes: “Unprecedented,” “Historic,” “Blockbuster,” “Tipping Point,” “Sweeping,” “Ambitious,” “Major”
|
|
Grassley Statement on Committee Passage of Prescription Drug Pricing Reduction Act
|